SGLT2 Inhibitors Must be Discontinued by Patients Before Surgery
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved label changes for SGLT2 inhibitors. The FDA said that it recommends doctors advise patients to discontinue SGLT2 medications before surgery to reduce the possible risk for diabetic ketoacidosis. Healio.com reported that SGLT2 drug Invokana … [Read more...]
SGLT2 Inhibitors Fournier’s Gangrene
UNITED STATES – As reported in an online article published by Infectiousdiseaseadvisor.com, patients taking SGLT2 inhibitors to treat type 2 diabetes may be at risk of developing Fournier’s Gangrene, an infection of the genital area. According to study results published in the Annals of Internal Medicine, infections of the genital … [Read more...]
Farxiga and Xigduo Diabetes Drug Makers Face MDL in New York
The Judicial Panel on Multidistrict Litigation established a multidistrict litigation (MDL) in New York to hear claims of diabetic ketoacidosis and kidney damage allegedly caused by the Farxiga and Xigduo diabetes drugs. Farxiga and its sister drug Xigduo XR are manufactured by Bristol-Myers Squibb Co., AstraZeneca Pharmaceuticals … [Read more...]
Invokana and Other Diabetes Meds Raise Risk of Limb Amputations
Diabetes Meds Raise Risk Of Amputations. According to the European Medicines Agency (EMA), patients with diabetes who take Invokana, or other sodium-glucose cotransporter-2 (SGLT2) inhibitors may have an increased risk of lower limb amputations, especially the toes. Diabetes medications cited include Invokana (canagliflozin), … [Read more...]
Lawsuit Alleges Invokana Responsible for Diabetic Ketoacidosis Injury
A lawsuit filed against Johnson & Johnson and its subsidiary, Janssen, alleges that the Janssen diabetes medication, Invokana, causes patients to develop diabetic ketoacidosis. The lawsuit was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana (canagliflozin) … [Read more...]
